Jiankui they/them retweeted
If I’m Boston College I’m walking off the field. If this is a fumble, their touchdown that was called off earlier in the game is a touchdown. It is the same exactly play.
These refs are fishy to say the least.
Curve below is OS on PD1 retreat after progression by stage. 31% patients in IGNYTE were stage III which isn't even on here. Note Opdualag is comparator which has 20% risk reduction vs PD1 in 1L. When you adjust for these factors, it is unclear if RP1 is adding much/wins in RCT.
$repl- oh the irony... Nice timing (for those who claimed RP1 responses were a fluke) #asco26
3
612
$REPL crazy how the FDA published the CRL from a team under Pazdur citing trial design as a no-go and ppl on here acting like FDA accepting resub is 'right thing to do'. Let be honest there is no objective rationality for AA here, this is politics.
3
18
2,473
i hesitate to "dump" on @adamfeuerstein. i'm sure he means well! but this post confirms his core skill is mistaking condescension for expertise. he knows very little about prediction markets, incentive design, or what biotech desperately needs. old man, please reconsider.
1
7
844
$RVMD Did they comment on therapeutic index? Not sure how a more potent drug plays here when on target tox limited dose of the first gen…
New compound from @RevMedicines RM-055 disclosed at #AACR26
They took a subtle finding 👉🏽Daraxonrasib-CYPA complex modestly increasing RAS GTP hydrolysis 👉🏽 to build a RAS GAP on steroids. RM-055 flattens Daraxonrasib resistant tumors including RAS amplified cases across models.
1
6
3,304
btw $LRMR almost has no shot at AA. Skin fxn is not surrogate for CNS fxn, mFARS improvements in nonamb patients likely just placebo/noise, wont have 30 patients at 6m at filing because 36% discon rate in OLE, modified dosing regimen will only have data in handful of patients..
6
20
5,562
Straight up lying that fda rugpulled them when they said trial would be unapprovable in 2021. Making 4m a year. What an asshole. At what point do these guys start getting prosecuted for securities fraud?
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of @Replimune walks us through the program's timeline and history, and what this might mean for its future. $REPL
Full video: biotechtv.com/post/sushil-pa…
$REPL CRL is WILD...these guys lied for fucking years. Also FDA is absolutely correct here, management story never made sense, cant comp Gr3 to Gr4 population. Also censoring PD in retreated patients is dirty. V little chance this beats opdualag on OS imo this company should die.
Looks like @DrPatrick blocked me like he did Cynviloq. Too bad anktiva can’t enhance the body’s ability to not be a massive pussy.
1
8
505
Turns out the dog guys vaccine was given concomitant with pd1 and looking for investors…so basically the classic single arm io combo grift has now come to n=1 dog studies. Probably wasn’t even his dog tbh
Very techbro of the dog guy to sequence and use alphafold to find a bespoke therapy for a cancer that is almost unilaterally driven by KIT which has multiple approved inhibitors
IMO $CRVS drug looks inert on cytokine/T cell compartment (data slice & dice). Even if you don’t agree why did the first 2 cohorts with no action on biomarkers show efficacy on EASI? Company unblinded, CEO says last cut TARC doesn’t matter/il4 can’t be measured but have it now…
1
18
3,964
This is a masterclass in misinterpreting data
$NRIX +23% surprises me. I thought the #ASH25 data showed $ONC to be better on efficacy (with caveats), albeit worse on safety. My earlier take on @ApexOnco -> oncologypipeline.com/apexonc…
2
1,206
1. You've generated 0 evidence to prove claims. The post-hoc from IASCLC is retarted.
2. PD1+chemo sig better on OS/PFS HR vs PD1 alone, disproving this theory.
3. Your company is going to 0 unless you can put the screws on daddy trump. V transparent.
Shit makes my blood boil
unavailable
Great news for $IBRX! Anktiva is the perfect bespoke therapy for the rare population of patients that don’t want to live!
unavailable
1
6
1,496



















